Search - tctmd.com

Displaying 121 - 140 of 177

Sort: Relevancy | Date

News Features

ISCHEMIA Fracas: Amid Charges of Moving the Goalposts, Investigators Come Out Swinging

Michael O'Riordan

March 23, 2018

News Conference News ACC 2018

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

Michael O'Riordan

March 20, 2018

News Conference News ACC 2018

Precision Medicine Gamble Fails for CETP Inhibitors in ACCELERATE Analysis

Michael O'Riordan

March 14, 2018

News Conference News ACC 2018

Gout Drug Febuxostat Linked to More CV Deaths Without Uptick in CV Events: CARES Trial

Caitlin E. Cox

March 14, 2018

News Conference News ACC 2018

Canakinumab Falls Short of Halting Progression to Diabetes in Patients at Risk: CANTOS

Michael O'Riordan

March 12, 2018

News Conference News ACC 2018

ODYSSEY Delivers a Win for Alirocumab in ACS, With a Signal of Survival Benefit

Michael O'Riordan

March 10, 2018

News Conference News ACC 2018

ACC 2018, Day One: Live From Orlando! The ODYSSEY Begins

Shelley Wood

March 10, 2018

News Conference News ACC 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Shelley Wood

March 05, 2018

News Conference News ACC 2018

Flu Vaccine Reduces Mortality, Hospitalization in HF Patients: Meta-analysis

Michael O'Riordan

March 01, 2018

News Daily News

Symptomatic Myocardial Ischemia but No Obstructive CAD: Some Drugs Work, Others Don’t, Review Finds

Caitlin E. Cox

January 18, 2018

News Daily News

It’s Official: Evolocumab Gains Claim for CVD Event Reduction

Michael O'Riordan

December 04, 2017

News Features

Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate

Michael O'Riordan

November 27, 2017

News Conference News AHA 2017

Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear

Todd Neale

November 14, 2017

News Conference News AHA 2017

Two FOURIER Subgroup Analyses Show Added Benefit of Evolocumab in Those With PAD, Prior MI

Yael L. Maxwell

November 13, 2017

News Daily News

Evolocumab ‘Abjectly Fails’ Another Financial Stress Test

Michael O'Riordan

October 19, 2017

News Daily News

Secondary Prevention Lagging Behind in Women With Established Coronary Disease

Todd Neale

September 22, 2017

News Industry News

New FOURIER Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With Diabetes

September 15, 2017

News Conference News ESC 2017

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

Michael O'Riordan

August 28, 2017

News Conference News ESC 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Michael O'Riordan

August 27, 2017

News Daily News

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

Michael O'Riordan

August 08, 2017

Advertisement

ISCHEMIA Fracas: Amid Charges of Moving the Goalposts, Investigators Come Out Swinging

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

Precision Medicine Gamble Fails for CETP Inhibitors in ACCELERATE Analysis

Gout Drug Febuxostat Linked to More CV Deaths Without Uptick in CV Events: CARES Trial

Canakinumab Falls Short of Halting Progression to Diabetes in Patients at Risk: CANTOS

ODYSSEY Delivers a Win for Alirocumab in ACS, With a Signal of Survival Benefit

ACC 2018, Day One: Live From Orlando! The ODYSSEY Begins

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Flu Vaccine Reduces Mortality, Hospitalization in HF Patients: Meta-analysis

Symptomatic Myocardial Ischemia but No Obstructive CAD: Some Drugs Work, Others Don’t, Review Finds

It’s Official: Evolocumab Gains Claim for CVD Event Reduction

Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate

Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear

Two FOURIER Subgroup Analyses Show Added Benefit of Evolocumab in Those With PAD, Prior MI

Evolocumab ‘Abjectly Fails’ Another Financial Stress Test

Secondary Prevention Lagging Behind in Women With Established Coronary Disease

New FOURIER Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With Diabetes

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content